Glycine regulates inflammatory markers modifying the energetic balance through PPAR and UCP-2

Biomedicine and Pharmacotherapy

Volumn 64, Issue 8, 2010, Pages 534-540

  Almanza Perez, J C ^a   Alarcon Aguilar, F J ^a   Blancas Flores, G ^b   Campos Sepulveda, A E ^c   Roman Ramos, R ^a   Garcia Macedo, R ^b   Cruz, M ^b  

^a DEPARTAMENTO DE QUÍMICA   (Mexico)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Glycine; Monosodium glutamate; PPARs

Indexed keywords

ADIPONECTIN; GLUTAMATE SODIUM; GLYCINE; INSULIN; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ADIPOSE TISSUE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GLYCINE; INSULIN; INTERLEUKIN-6; ION CHANNELS; LEPTIN; MICE; MITOCHONDRIAL PROTEINS; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM GLUTAMATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956877625     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.04.047     Document Type: Article

References (52)

1. Fantuzzi G., Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 2007, 27:996-1003.
2. Haffner S.M. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity 2006, 14(Suppl. 3):121S-127S.
3. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939-949.
4. Wellen K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003, 112:1785-1788.
5. Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001, 60:329-339.
6. Rosen E.D., Spiegelman B.M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006, 444:847-853.
7. Ahima R.S. Adipose tissue as an endocrine organ. Obesity 2006, 14:242S-249S.
8. Trifilieff A., Bench A., Hanley M., Bayley D., Campbell E., Whittaker P. PPAR-α and -γ but not -δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kB independent effect. British J Pharmacol 2003, 139:163-171.
9. Kersten S., Desvergne B., Wahli W. Roles of PPAR in health and disease. Nature 2000, 405:421-424.
10. Lowell B.B. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell 1999, 99:239-242.
11. Evans R.M., Barish G.D., Wang Y.X. PPAR and the complex journey to obesity. Nat Med 2004, 10:355-361.
12. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 2001, 276:41245-41254.
13. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001, 7:941-946.
14. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004, 30:13-19.
15. Fatehi-Hassanabad Z., Chan C. Transcriptional regulation of lipid metabolism by fatty acids: a key determinant of pancreatic β-cell function. Nutr Metab 2005, 2:1-12.
16. Desautels M., Zaror-Behrens G., Himms-Hagen J. Increased purine nucleotide binding, altered polypeptide composition and thermogenesis in brown adipose tissue mitochondria of cold-acclimated rats. Can J Biochem 1978, 56:378-383.
17. Li B., Nolte L.A., Ju J.-S., Han D.-H., Coleman T., Holloszy J.O., et al. Skeletal muscle respiratory uncoupling prevents diet induced obesity and insulin resistance in mice. Nat Med 2000, 6:1115-1120.
18. Matilla B., Matriz J.L., Culebras J.M., Gallego J., Gonzalez P. La glicina: un nutriente antioxidante protector celular. Nutr Hosp 2002, 1:2-9.
19. Garcia-Macedo R., Sanchez-Muñoz F., Almanza-Perez J.C., Duran-Reyes G., Alarcon-Aguilar F.J., Cruz M. Glycine increases mRNA adiponectin and diminishes pro-inflammatory adipokines expression in 3T3-L1 cells. Eur J Pharmacol 2008, 587:317-321.
20. Alarcon-Aguilar F.J., Almanza-Perez J.C., Blancas G., Angeles S., Garcia-Macedo R., Roman R., et al. Glycine regulates the production of pro-inflammatory cytokines in lean and monosodium glutamate-obese mice. Eur J Pharmacol 2008, 599:152-158.
21. Fasshauer M., Klein J., Lossner U., Paschke R. Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes. Horm Metab Res 2003, 35:147-152.
22. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003, 301:1045-1050.
23. Dehoux M.J., Van Beneden R.P., Fernandez-Celemin L., Lause P.L., Thiissen J.P. Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle alter LPS injection. FEBS Lett 2003, 544:214-217.
24. Hirata A.E., Andrade I.S., Vaskevicius P., Dolnikoff M.S. Monosodium glutamate (MSG)-obese rats develop glucose intolerance and insulin resistance to peripheral glucose uptake. Braz J Med Biol Res 1997, 30:671-674.
25. De Mello M., de Souza C.T., Braga L.R., dos Santos J.W., Ribeiro I.A., Gobatto C.A. Glucose tolerance and insulin action in monosodium glutamate (MSG) obese exercise-trained rats. Physiol Chem Phys Med NMR 2001, 33:63-71.
26. Dolnikoff M., Martín-Hidalgo A., Machado U.F., Lima F.B., Herrera E. Decreased lipolysis and enhanced glycerol and glucose utilization by adipose tissue prior to development of obesity in monosodium glutamate (MSG) treated-rats. Int J Obes 2001, 25:426-433.
27. Nagata M., Susuki W., Iisuka S., Takeda S., Aburada M., Miyamoto K. Type 2 diabetes mellitus in obese mice model induced by monosodium glutamate. Exp Anim 2006, 55:109-115.
28. Nakanishi Y., Tsuneyama K., Fujimoto M., Salunga T.L., Nomoto K., An J.L., et al. Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia. J Autoinmmun 2008, 30:42-50.
29. Perello M., Gaillard R.C., Chisari A., Spinedi E. Adrenal enucleation in MSG-damaged hyperleptinemic male rats transiently restores adrenal sensitivity to leptin. Neuroendocrinol 2003, 78:176-184.
30. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
31. Lappas M., Permezel M., Rice G.E. Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2. Endocrinol 2005, 146:3334-3342.
32. Armoni M., Harel C.H., Karni S., Chen H., Bar-Yoseph F., Ver M.R., et al. FOXO1 Represses PPARγ1 and PPARγ2 gene promoters in primary adipocytes: a novel paradigm to increase insulin sensitivity. J Biol Chem 2006, 281:19881-19891.
33. Gustafson B., Jack M.M., Cushman S.W., Smith U. Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 2003, 308:933-939.
34. Leiter L.A. Pueden las tiazolidinedionas retrasar la progresión de la enfermedad en diabetes tipo 2?. Curr Med Res Op 2006, 22:1193-1201.
35. Ohama Y., Harada T., Iwabe T., Taniguchi F., Takenaka Y., Terakawa N. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells. Fertil Steril 2008, 89:311-317.
36. Caballero A.E. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Inv Med 2005, 36:241-249.
37. Fasshauer M., Paschke R. Regulation of adipokines and insulin resistance. Diabetologia 2003, 46:1594-1603.
38. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002, 51:2968-2974.
39. Zarate A., Saucedo R., Hernandez M. El receptor de peroxisoma-proliferadoractivador gamma (PPARγ) es un factor de transcripcion multigenico de versatilidad metabolica. Acta Medica 2005, 3:53-54.
40. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferatoractivated receptors and liver X receptor α in humans. Diabetes 1997, 46:1319-1327.
41. Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., et al. Activation of proliferatoractivated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998, 273:25573-25580.
42. Inove I., Shino K., Noji S., Awata T., Katayama S. Expression of peroxisome proliferator-activated receptor α in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998, 246:370-374.
43. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
44. Wang Y.-X., Zhang C.L., Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004, 2:e294.
45. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M., et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 2006, 103:3444-3449.
46. Michalik L., Desvergne B., Tan N.S., Basu-Modak S., Escher P., Rieusset J., et al. Impaired skin wound healing in peroxisome proliferator activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 2001, 154:799-814.
47. Takata Y., Liu J., Yin F., Collins A., Lyon C., Lee C.H., et al. PPAR-δ mediated anti-inflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. PNAS 2008, 105:4277-4282.
48. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., et al. PGC-1[alpha]-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273.
49. Patti M.E., Butte A.J., Crunkhorn S., Cusi K., Berria R., Kashyap S., et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 2003, 100:8466-8471.
50. Rolfe D.F., Brand M.D. Contribution of mitochondrial proton leak to skeletal muscle respiration and to standard metabolic rate. Am J Physiol Cell Physiol 1996, 271:C1380-C1389.
51. Jiang Y., Zhang H., Dong L.Y., Wang D., An W. Increased hepatic UCP2 expression in rats with nonalcoholic steatohepatitis is associated with upregulation of Sp1 binding to its motif within the proximal promoter region. J Cell Biochem 2008, 105:277-289.
52. Chan C.B., Saleh M.C., Koshkin V., Wheeler M.B. Uncoupling protein 2 and islet function. Diabetes 2004, 53(Suppl. 1):S136-S142.